Altimmune Inc ALT:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
Last | 10:00 AM EDT
12.28quote price arrow down-0.62 (-4.81%)
Volume
220,100
52 week range
2.88 - 35.10

...

Loading . . .
  • Open12.96
  • Day High13.00
  • Day Low12.14
  • Prev Close12.90
  • 52 Week High35.10
  • 52 Week High Date07/20/20
  • 52 Week Low2.88
  • 52 Week Low Date05/01/20

Key Stats

  • Market Cap456.20M
  • Shares Out37.15M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta1.62
  • YTD % Change10.37

KEY STATS

  • Open12.96
  • Day High13.00
  • Day Low12.14
  • Prev Close12.90
  • 52 Week High35.10
  • 52 Week High Date07/20/20
  • 52 Week Low2.88
  • 52 Week Low Date05/01/20
  • Market Cap456.20M
  • Shares Out37.15M
  • 10 Day Average Volume0.86M
  • Dividend-
  • Dividend Yield-
  • Beta1.62
  • YTD % Change10.37

RATIOS/PROFITABILITY

  • EPS (TTM)-2.02
  • P/E (TTM)-6.07
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-54.501M
  • ROE (MRQ)-36.14%
  • Revenue (MRQ)8.19M
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-599.20%
  • Debt To Equity (MRQ)0.00%

EVENTS

  • Earnings Date05/11/2021
  • Ex Div Date02/06/2017
  • Div Amount2.91
  • Split Date-
  • Split Factor-

Latest From Altimmune Inc

There is no recent news for this security.

Profile

MORE
Altimmune Inc is a clinical-stage immunotherapeutics company. The Company is focused on the development of products to stimulate robust and durable immune responses for the prevention and treatment of disease. The Company’s product candidates include ALT-801, HepTcell, ALT-702, NasoVAX and NasoShield. HepTcell is a synthetic peptide immunotherapeutic candidate designed to break immune tolerance in chronic Hepatitis B infection. ALT-702, a TLR7/8 agonist conjugate, is a tumor...
Mitchel Sayare Ph.D.
Chairman
Vipin Garg Ph.D.
President
William Brown CPA
Chief Financial Officer
Address
910 Clopper Rd Ste 201S
Gaithersburg, MD
20878-1361
United States

Top Peers

SYMBOLLASTCHG%CHG
KALV
Kalvista Pharmaceuticals Inc
25.43-0.72-2.75%
KALA
Kala Pharmaceuticals Inc
6.93-0.64-8.45%
EVLO
Evelo Biosciences Inc
11.45+1.41+14.04%
AVRO
AVROBIO Inc
11.16-0.16-1.41%
RAPT
Rapt Therapeutics Inc
20.42-0.62-2.97%